PA
TVTX icon

Perceptive Advisors’s Travere Therapeutics TVTX Stock Holding History

Perceptive Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-100,000
Closed -$3.31M – 185
2015
Q2 		$3.31M Buy
+100,000
New +$2.74M 0.2% 80

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Perceptive Advisors's TVTX Position: Q1 2026 in Review

Perceptive Advisors reduced its Travere Therapeutics (TVTX) stake by 3.2% in Q1 2026, selling an estimated $4.05M and leaving 4,142,551 shares worth $123M. The position accounts for 2.41% of the portfolio, ranked #12.

Perceptive Advisors first reported a position in TVTX in Q1 2014 and has held it in 44 quarters since. The position peaked at $163M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Perceptive Advisors held 4,142,551 shares of Travere Therapeutics worth $123M as of Q1 2026.
  • Perceptive Advisors sold 135,629 Travere Therapeutics shares in Q1 2026, an estimated $4.05M.
  • Travere Therapeutics made up 2.41% of Perceptive Advisors's portfolio in Q1 2026, its #12 holding.
  • Perceptive Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 44 quarters since.
  • Perceptive Advisors's Travere Therapeutics position peaked at $163M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.